Tirzepatide is a prescription peptide therapy that targets both GLP-1 and GIP receptors. It helps regulate appetite, improve satiety, support blood sugar control, and promote weight management.

By activating both GLP-1 and GIP pathways, Tirzepatide signals the brain to reduce hunger, slows gastric emptying, and helps the body manage glucose more effectively, supporting healthier weight and metabolic function.

Tirzepatide is typically given as a once-weekly subcutaneous injection under the guidance of a licensed healthcare provider to ensure safety and proper dosing.

When prescribed and monitored by a healthcare professional, Tirzepatide is generally safe. Common side effects may include mild gastrointestinal symptoms such as nausea, vomiting, or diarrhea, which usually subside over time.